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 MicroRNAs (miRNAs) are small non-coding RNAs that interact with 3’UTR regions of 
target mRNAs resulting in translational repression and/or messenger destabilization 
[1]. These small RNA molecules hold a huge regulatory potential since each of them 
controls the level of hundreds of targets. Alterations of expression or activity of 
miRNAs have a major impact on cellular functions and contribute to the development 
of human diseases [1]. Recent studies highlighted an unsuspected interconnection 
between miRNAs and blood lipoproteins that opens new therapeutic perspectives for 
the treatment of dyslipidemias. 
Regulation of fatty acid metabolism is an important component in homeostasis 
maintenance. This is achieved by master controllers such as SREBPs (sterol 
regulatory element-binding proteins) that are transcription factors governing the 
expression of key enzymes in the lipid synthesis pathways and the production of 
blood lipid carriers (e.g. very low density lipoproteins [VLDLs], high density 
lipoproteins [HDLs]) [2]. miRNAs are now also emerging as key players in lipid 
metabolism regulation (reviewed in [3]). A series of recent articles unveiled an 
important connection between, on one hand, fatty acid and cholesterol metabolism 
and transport and, on the other hand, miR-33, a miRNA encoded by an intron of the 
gene coding for SREBP-2 that positively regulates the expression of many genes 
involved in cholesterol biosynthesis [2]. Mice lacking miR-33 express more of the 
ABCA1 transporter that loads cholesterol on HDLs and display higher serum HDL 
levels [4]. miR-33 represses at least two sets of genes relevant for lipid homeostasis: 
those involved in cholesterol metabolism and cellular efflux to HDLs (ABCA1, 
ABCG1, and NPC1) and those implicated in fatty acid metabolism (CPT1α, CROT, 
HADHB, and AMPK1α) [5-7, 8**]. Consequently, miR-33 participates in lowering HDL 
levels by diminishing the efflux of cholesterol to nascent HDL particles and decreases 
fatty acid oxidation, favoring lipid and triglyceride accumulation. miR-33 also perturbs 
proper insulin signaling by targeting the insulin receptor substrate 2-encoding mRNA 
[8**]. 
These properties make miR-33 an ideal target for the development of compounds to 
treat the metabolic syndrome characterized by decreased HDL levels, increased 
triglyceride and glucose blood levels. Increasing HDLs levels would also be beneficial 
in the context of atherosclerosis as HDLs can remove cholesterol from atheromatous 
plaques [9]. The clinical relevance of antagonizing miR-33 was demonstrated in mice 
and African green monkeys treated with an anti-miR-33 oligonucleotide. In mice, this 
resulted in increased circulating levels of HDLs and regression of atherosclerosis 
[10**]. In African green monkey, HDL levels were also raised with a concomitant 
decrease in VLDL levels [11*]. 
SREBP-2 is activated post-transcriptionally when cells are low in cholesterol but the 
transcription of its own gene is also turned on in these conditions [2]. As indicated 
above, miR-33 is encoded by an SREBP2 intron. Hence, when SREBP-2 is induced 
to promote cholesterol synthesis, the concomitant expression of miR-33 ensures, via 
down-regulation of ABCA1 for example, that cholesterol is not exported out from cells 
that are in need of this lipid. This is not the only interconnection between HDLs and 
miRNAs. Indeed, miRNAs use HDLs to travel in the blood and to reach distant 
tissues [12**]. Transfer of miRNAs from HDLs to the acceptor cells requires the 
scavenger receptor class B type I (SR-BI) [12**]. Interestingly, the HDL-miRNA profile 
of healthy subjects differs from that of patients suffering from atherosclerosis [12**]. 
Determination of which miRNAs are carried by HDLs represents therefore an 
attractive diagnostic tool to determine if a person has developed, or is at risk of 
developing, a given metabolic pathology. 
As demonstrated in the studies described above, miR-33 controls HDL production 
which in turn favors the transport of miRNAs in the circulation. Even though miR-33 
itself seems not to be incorporated in newly produced HDL particles [12**], it 
increases the capacity of other miRNAs to take a ride on HDLs to act on distant 
tissues. Thus, the partnership between HDLs and miR-33 would extend the response 
to changes in lipid homeostasis far beyond the cells initially producing the lipoprotein 
particles. From this point of view, HDL-associated miRNAs would elevate their statute 
from useful biomarkers to a new class of hormones. 
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Recommended reading 
Two bullets:  8.  Davalos A, Goedeke L, Smibert P et al. miR-33a/b 
contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl 
Acad Sci U S A 2011; 108:9232-9237. 
This study provides evidence that miR-33 is co-expressed with his hosting gene 
SREBP-2 and that it targets ABCA1 and ABCG1 mRNAs. Overexpression of miR-33 
reduces HDL levels and cholesterol efflux while silencing of this miRNA has opposing 
effects. The importance of this work is that it shows a two-tiered control of a given 
metabolic pathway – lipid synthesis in the present case – from a single locus via the 
expression of a transcription factor (SREBP-2) and a miRNA (miR-33). 
 
Two bullets:  10.  Rayner KJ, Sheedy FJ, Esau CC et al. Antagonism of 
miR-33 in mice promotes reverse cholesterol transport and regression of 
atherosclerosis. J Clin Invest 2011; 121:2921-2931. 
This study demonstrates that blockade of miR-33 in mice leads to increased 
circulating HDL levels and to enhanced cholesterol transport to liver and feces. 
Moreover, mice treated with anti-miR-33 displayed reduced atherosclerotic plaque 
sizes and decreased inflammation. This work and the data presented in reference 11 
support the notion that miRNA inhibition is a potential therapeutic tool to treat 
metabolic diseases. 
 
One bullet: 11.  Rayner KJ, Esau CC, Hussain FN et al. Inhibition of miR-33a/b in 
non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011; 
478:404-407. 
In contrast to mice, large mammals express two miR-33 isoforms. This study 
demonstrates that inhibition of both miR-33 isoforms permits to raise HDL and lower 
VLDL levels in African monkeys. These beneficial effects further confirm the 
therapeutic potential of anti-miR-33 for the treatment of dyslipidemias in primates. 
 
Two bullets: 12.  Vickers KC, Palmisano BT, Shoucri BM et al. MicroRNAs are 
transported in plasma and delivered to recipient cells by high-density lipoproteins. 
Nat Cell Biol 2011; 13:423-433. 
This is the first demonstration that circulating HDLs transport a large number of 
miRNAs that can be delivered in active form to recipient cells through a receptor-
dependent process. These original findings suggest that HDL-mediated delivery of 
miRNAs represents a novel cell-to-cell communication mechanism. The HDL-miRNA 
profile differs between healthy and hypercholesterolemia subjects and may 
potentially be used as a new diagnostic tool. 
 
